Improvement of Liver Function in Liver Cirrhosis Patients After Autologous Mesenchymal Stem Cell Injection:a Phase I-II Clinical Trial

A Phase One/Two Clinical Trial on the Use of Autograft Mesenchymal Stem Cells Differentiated Into Progenitor of Hepatocytes for the Salvage Treatment of Patients With End-stage Liver Disease

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00420134

Enrollment

Registered

2007-01-09

Start date

2006-02-28

Completion date

2009-06-30

Last updated

2009-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis, Liver Failure

Keywords

mesenchymal stem cell, end stage liver disease, Cirrhosis, stem cell therapy

Brief summary

The methods for separation of mesenchymal stem cell were established in 2001. These cells can differentiate to osteocytes, hepatocytes, chondrocytes, myocytes and etc,. In this study the investigators try to separate mesenchymal stem cell from end stage liver disease, then these cells will be differentiated to progenitor of hepatocytes, finally , the investigators injected these cells into portal vein under ultrasound guide. The investigators determine the effects of injected cells in reestablishment of liver function.

Interventions

PROCEDUREinjection of progenitor of hepatocyte drived from Mesenchymal stem cell

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

SINGLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* MELD score of at least 10 * Patent portal vein on color Doppler examination of the liver * Normal alpha-feto protein serum levels * Age more than 18 * Filling inform consent by patients and first degree family members

Exclusion criteria

* Any evidence of hepatocellular carcinoma on liver ultrasound studies * Patients want to exclude from study

Design outcomes

Primary

Measure	Time frame
Liver function test	—
MELD score	—

Secondary

Measure	Time frame
Cirrhosis mortality after 6 months	—

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026